



ITPCru

International Treatment Preparedness Coalition
Eastern Europe and Central Asia

To: Chief executive officer Severin Shwan
Chairman of the board of directors Dr Franz B. Humer
F. Hoffmann-La Roche

Statement by the Eastern European and Central Asian Community Advisory Board to Roche

The main obstacle to access to treatment for 7 million people living with Hepatitis C in Eastern Europe and Central Asia is the unacceptable and unfair pricing policy of the pharmaceutical companies. The treatment of Hepatitis C costs \$15 000 in the region, which in its own right deprives people from obtaining it and thus staying alive.

We, the members of the Eastern European and Central Asian Community Advisory Board, call upon all manufacturers of pegylated interferons, including Roche, to reduce now the cost of a Hepatitis C treatment course to \$2000 per patient in Eastern Europe and Central Asia, so that people can survive.

Signatures:

Organizations and initiative groups

International Treatment Preparedness Coalition in EECA (ITPCru)

Eastern European and Central Asian Union for PLWH (ECUO PLWH)

Belorussian CAB

Moldavian CAB

Russian CAB

Ukrainian CAB

Estonian CAB

Public union to fight AIDS, Azerbaijan

Armenian Network of Positive People

Public Organization "Real World Real People", Armenia

Union of public organizations "Group on advocacy for AIDS problems", Armenia

Republican public union "Belorussian community of PLWH"

Charitable public organization "Alternative", Belorussia

Public organization "Real People Real Vision", Georgia

Georgian Harm Reduction Network

Organization of people living with Hepatitis C, Georgia

Public organization "New Vector", Georgia

Public organization «Union Tanadgoma», Georgia

Public organization "Georgian plus group", Georgia

All-Russian Public Organization "Union of PLWH"

League of PLWH in Moldova

Estonian Network of PLWH